公开(公告)号：WO2017070624A1

公开(公告)日：2017-04-27

申请号：PCT/US2016/058324

申请日：2016-10-21

Applicant: MODERNATX, INC.

Inventor： CIARAMELLA, Giuseppe ,  HIMANSU, Sunny ,  HUANG, Eric, Yi-Chun ,  ZAKS, Tal

IPC: A61K9/10 ,  A61K48/00 ,  A61K39/00 ,  A61K39/12

CPC classification number: A61K39/12 ,  A61K9/0019 ,  A61K9/1271 ,  A61K9/513 ,  A61K39/015 ,  A61K39/39 ,  A61K39/42 ,  A61K48/00 ,  A61K2039/51 ,  A61K2039/5254 ,  A61K2039/53 ,  A61K2039/55511 ,  A61K2039/55555 ,  A61K2039/575 ,  C12N2770/24034 ,  C12N2770/24134 ,  C12N2770/36134

Abstract: The disclosure relates to tropical diseases such as viral mosquito borne illnesses and the treatment thereof. The invention includes ribonucleic acid vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines for treating and preventing tropical disease.

Abstract translation: 本公开涉及热带病如病毒性蚊媒疾病及其治疗。 本发明包括核糖核酸疫苗和组合疫苗，以及将疫苗和包含疫苗的组合物用于治疗和预防热带病的方法。

公开(公告)号：WO2015089590A1

公开(公告)日：2015-06-25

申请号：PCT/AU2014/050439

申请日：2014-12-19

Applicant: THE UNIVERSITY OF QUEENSLAND

Inventor： YU, Chengzhong ,  MITTER, Neena ,  ZHANG, Jun

IPC: C08G77/22 ,  C08K3/34 ,  C08K3/36 ,  B82Y30/00 ,  B82Y40/00 ,  A61K9/14 ,  A61K9/32 ,  A61K9/50 ,  A61K9/51 ,  A61K9/52 ,  A61K47/00 ,  A61K47/02 ,  A61K47/30 ,  A61K47/32 ,  A61K47/34 ,  A61K47/48 ,  C01B33/00 ,  A61K9/00 ,  C01B13/14 ,  C01B13/16 ,  C01B13/36

CPC classification number: A61K9/501 ,  A61K9/5031 ,  A61K9/5115 ,  A61K9/5146 ,  A61K39/12 ,  A61K39/39 ,  A61K2039/55505 ,  B01J13/10 ,  B82Y30/00 ,  B82Y40/00 ,  C01B33/18 ,  C01P2004/34 ,  C01P2004/64 ,  C01P2006/16 ,  C12N2770/24034

Abstract: The invention relates, in part, to a method of producing silica vesicles including under controlled conditions to thereby heavily influence the morphology and characteristics of the vesicles. The vesicles are shown to be effective as delivery agents for chemical and biological agents. They are also shown to be useful in methods of treatment and as components of an immunogenic composition.

Abstract translation: 本发明部分涉及在控制条件下制备二氧化硅囊泡的方法，从而严重影响囊泡的形态和特征。 显示出囊泡作为化学和生物制剂的递送剂是有效的。 它们也被证明可用于治疗方法和作为免疫原性组合物的组分。

公开(公告)号：WO2016210127A1

公开(公告)日：2016-12-29

申请号：PCT/US2016/039011

申请日：2016-06-23

Applicant: TECHNOVAX, INC.

Inventor： GALARZA, Jose M. ,  BOIGARD, Helene ,  MARTIN, George

IPC: A61K39/12 ,  A61K39/145 ,  A61K47/22

CPC classification number: A61K39/12 ,  A61K39/145 ,  A61K2039/5258 ,  A61P31/14 ,  C07K14/005 ,  C12N7/00 ,  C12N9/506 ,  C12N2770/24023 ,  C12N2770/24034 ,  C12N2770/24134 ,  Y02A50/386 ,  Y02A50/388 ,  Y02A50/39 ,  Y02A50/392 ,  Y02A50/394

Abstract: Described herein are flavivirus virus-like particles (VLPs) that display on their surfaces antigenic flavivirus proteins. Also described are methods of making and using these VLPs.

Abstract translation: 本文描述的是黄病毒病毒样颗粒（VLPs），其在其表面上显示抗原性黄病毒蛋白。 还描述了制造和使用这些VLP的方法。

公开(公告)号：WO2009024567A1

公开(公告)日：2009-02-26

申请号：PCT/EP2008/060834

申请日：2008-08-19

Applicant: GLAXO GROUP LIMITED ,  UDEN, Mark ,  KOTSOPOULOU, Ekaterini

Inventor： UDEN, Mark ,  KOTSOPOULOU, Ekaterini

IPC: C07K16/18 ,  C12N15/67

CPC classification number: C12N15/85 ,  A61K39/12 ,  A61K2039/525 ,  C07K16/00 ,  C07K16/18 ,  C07K2317/41 ,  C07K2317/56 ,  C12N7/02 ,  C12N15/67 ,  C12N2770/24034 ,  C12N2770/24051 ,  C12N2800/60 ,  C12N2830/40

Abstract: The present invention provides methods of reducing the levels of a titratable selectable pressure required, the number of amplification cycles, and the time taken to generate protein expressing cell lines by altering the codons of the desired open-reading-frames. Through the use of codon adaptation for this purpose the methods of the invention consistently provide sufficient yields in faster time frames saving many weeks in cell line development activities. Furthermore the methods of the invention also generate cell lines with lower concentrations of selection and amplification agent than previously achievable. Accordingly lower levels of selection and amplification marker in the final cells lines are observed.

Abstract translation: 本发明提供了通过改变期望的开放阅读框的密码子来降低所需的可滴定可选择压力水平，扩增循环次数以及产生蛋白质表达细胞系所花费的时间的方法。 通过为此目的使用密码子适配，本发明的方法在更快的时间内始终提供足够的产量，从而在细胞系发育活动中节省了许多个星期。 此外，本发明的方法还产生具有比先前可实现的更低浓度的选择和扩增剂的细胞系。 因此，观察到最终细胞系中选择和扩增标记的较低水平。

公开(公告)号：WO1997037686A1

公开(公告)日：1997-10-16

申请号：PCT/AT1997000068

申请日：1997-04-08

Applicant: IMMUNO AKTIENGESELLSCHAFT ,  DORNER, Friedrich ,  BARRETT, Noel ,  EIBL, Johann

Inventor： IMMUNO AKTIENGESELLSCHAFT

IPC: A61K39/12

CPC classification number: A61K39/12 ,  A61K2039/5252 ,  A61K2039/55505 ,  A61L2/0011 ,  A61L2/08 ,  C12N7/00 ,  C12N15/10 ,  C12N2740/16034 ,  C12N2770/24034 ,  C12N2770/24061 ,  C12N2770/24134

Abstract: The invention concerns a process for disintegrating any biologically active nucleic acid in a biological material. According to the invention, a biologically active material is exposed one or a plurality of times to a laser beam in order essentially to disintegrate the entire biologically active nucleic acid in this biological material, whilst the biological integrity and activity of the biological material are retained.

Abstract translation: 本发明涉及一种用于任何生物活性核酸在生物材料，其中生物活性物质的激光束进行崩解所有生物学活性的核酸在该生物材料的一个或更多次是基本上崩解，而生物完整性 和生物材料的活性得以维持。

公开(公告)号：WO2017195919A1

公开(公告)日：2017-11-16

申请号：PCT/KR2016/005037

申请日：2016-05-12

Applicant: 주식회사 바이오앱 ,  대한민국(농림축산식품부 농림축산검역본부장)

Inventor： 안동준 ,  임성인 ,  송재영 ,  정혜영 ,  손은주 ,  황인환 ,  박남조 ,  이용직 ,  김남형 ,  구성민

IPC: C12N15/82 ,  C07K14/005 ,  A61K39/12 ,  A23K20/147 ,  G01N33/569

CPC classification number: C12N15/8258 ,  A23K20/142 ,  A23K20/147 ,  A23K20/174 ,  A23K50/30 ,  A61K39/12 ,  A61K39/145 ,  A61K2039/517 ,  C07K14/005 ,  C07K14/11 ,  C12N15/8205 ,  C12N15/8257 ,  C12N2770/24034 ,  C12N2770/24322 ,  C12N2770/24334 ,  C12N2770/24351 ,  G01N33/56983 ,  G01N2333/183

Abstract: 본 발명은 식물 유래 돼지 열병 항원 pmE2 단백질 생산용 재조합 벡터, 상기 재조합 벡터로 형질전환된 식물체, 상기 식물체에서 발현된 식물 유래 돼지 열병 항원 pmE2 단백질 및 이의 용도에 관한 것이다. 본 발명에 따른 돼지 열병 바이러스의 GP55 단백질을 코딩하는 폴리뉴클레오티드; 및 셀룰로오즈 결합 도메인 단백질을 코딩하는 폴리뉴클레오티드를 포함하는 재조합 벡터; 및 상기 재조합 벡터로 형질전환된 식물체를 이용 시, 식물 유래 돼지 열병 항원 pmE2 단백질을 고효율로 생산할 수 있고, 다른 생산 방법에 비해 안전성 및 안정성이 있는 장점이 있다. 또한, 상기 식물 유래 돼지 열병 항원 단백질 pmE2는 셀룰로오즈 결합 도메인(cellulose-binding domain: CBD) 단백질을 포함하기 때문에, 돼지 열병 바이러스 노출 경로 및 항체 생성 경로를 판별하는데 있어 효과적인 마커로서 유용하게 이용될 수 있다.

Abstract translation:

本发明涉及来自植物的猪瘟抗原PME2蛋白质生产的重组载体，植物来源的猪瘟抗原PME2蛋白及其用途在植物中表达，用所述重组载体转化的植物 。 编码根据本发明的猪瘟病毒的GP55蛋白的多核苷酸; 包含编码纤维素结合域蛋白的多核苷酸的重组载体; 以及使用与所述重组载体转化的植物时，有可能产生来自植物的猪瘟抗原PME2蛋白具有效率高，有一个优点，即安全性和稳定性相对于其他的生产方法如。 另外，上述来自植物的猪瘟抗原蛋白PME2纤维素结合结构域（纤维素结合结构域：CBD）得，因为它含有蛋白质，确定猪瘟病毒曝光路径，和产生的抗体路径可以作为一种有效的标志物是有用 。

公开(公告)号：WO2014121132A1

公开(公告)日：2014-08-07

申请号：PCT/US2014/014284

申请日：2014-01-31

Applicant: THE OREGON STATE BOARD OF HIGHER EDUCATION acting by and through PORTLAND STATE UNIVERSITY ,  PROVIDENCE HEALTH & SERVICES-OREGON

Inventor： STEDMAN, Kenneth, M. ,  LAIDLER, James, R. ,  BAHJAT, Keith

IPC: A61K39/12

CPC classification number: A61K39/12 ,  A61K39/125 ,  A61K39/13 ,  A61K39/145 ,  A61K39/15 ,  A61K39/21 ,  A61K39/215 ,  A61K39/235 ,  A61K39/285 ,  A61K39/29 ,  A61K39/292 ,  A61K2039/525 ,  A61K2039/5252 ,  A61K2039/55505 ,  A61K2039/55561 ,  A61K2039/55566 ,  A61K2039/55588 ,  C12N7/00 ,  C12N2710/10021 ,  C12N2710/10034 ,  C12N2710/24121 ,  C12N2710/24134 ,  C12N2720/12321 ,  C12N2720/12334 ,  C12N2740/16021 ,  C12N2740/16034 ,  C12N2760/16021 ,  C12N2760/16034 ,  C12N2770/20021 ,  C12N2770/20034 ,  C12N2770/24021 ,  C12N2770/24034 ,  C12N2770/24221 ,  C12N2770/24234 ,  C12N2770/32421 ,  C12N2770/32434 ,  C12N2770/32621 ,  C12N2770/32634 ,  C12N2795/10134 ,  C12N2795/14034 ,  Y02A50/386 ,  Y02A50/388 ,  Y02A50/39 ,  Y02A50/394 ,  Y02A50/396 ,  Y02A50/466

Abstract: It is disclosed herein that viruses coated in silica retain infectivity and the capacity to induce an immune response in an infected host. In addition, silicifled virus is remarkably resistant to desiccation. Provided herein are methods of inducing a virus-specific immune response in a subject by administering to the subject an effective amount of silicified virus or silicified virus particles. Methods of enhancing a virus-specific cell-mediated immune response (such as aT cell-mediated immune response) in a subject by administering to the subject a silicified virus or silicified virus particles are also described herein. Further provided are immunogenic compositions comprising silicified virus or silicified virus particles, such as compositions useful as vaccines. The immunogenic compositions include a pharmaceutically acceptable carrier and/or an adjuvant.

Abstract translation: 本文公开了用二氧化硅包被的病毒保持感染性和在受感染宿主中诱导免疫应答的能力。 此外，硅化病毒对干燥具有显着的抗性。 本文提供了通过向受试者施用有效量的硅化病毒或硅化病毒颗粒来在受试者中诱导病毒特异性免疫应答的方法。 本文还描述了通过向受试者施用硅化病毒或硅化病毒颗粒来增强受试者中病毒特异性细胞介导的免疫应答（例如T细胞介导的免疫应答）的方法。 还提供了包含硅化病毒或硅化病毒颗粒的免疫原性组合物，例如可用作疫苗的组合物。 免疫原性组合物包括药学上可接受的载体和/或佐剂。

公开(公告)号：WO2012118559A2

公开(公告)日：2012-09-07

申请号：PCT/US2012000110

申请日：2012-02-28

Applicant: VAXLNNATE CORP ,  SONG LANGZHOU ,  LIU GE ,  TUSSEY LYNDA

Inventor： SONG LANGZHOU ,  LIU GE ,  TUSSEY LYNDA

IPC: C07K19/00 ,  A61K39/12 ,  C07K14/18 ,  C07K14/195

CPC classification number: A61K39/12 ,  A61K2039/6068 ,  A61K2039/70 ,  C07K14/005 ,  C07K14/255 ,  C07K2319/00 ,  C07K2319/735 ,  C12N2770/24034 ,  C12N2770/24122 ,  C12N2770/24134

Abstract: The present invention relates to immunogenic compositions and vaccines of flavivirus. In particular, the present invention relates to improved Dengue vaccines and the design and making of such vaccines that enhance immunogenicity of the vaccine. The vaccines and immunogenic compositions of the present invention relate to mixed head bivalent flagellin-dengue antigen fusion proteins which can be combined with other bivalent dengue antigen fusion proteins or monovalent dengue antigen fusion proteins to produce multivalent vaccine including tetravalent vaccines.

Abstract translation: 本发明涉及黄病毒的免疫原性组合物和疫苗。 特别地，本发明涉及改进的登革热疫苗以及增强疫苗免疫原性的这种疫苗的设计和制备。 本发明的疫苗和免疫原性组合物涉及可与其他二价登革热抗原融合蛋白或单价登革热抗原融合蛋白结合的混合头二价鞭毛蛋白登革热抗原融合蛋白，以产生包含四价疫苗的多价疫苗。

公开(公告)号：WO2007002470A2

公开(公告)日：2007-01-04

申请号：PCT/US2006024584

申请日：2006-06-23

Applicant: INTERVET INT BV ,  STERNER FRANK JAY ,  GOOVAERTS DANIEL GHISLENA EMIE ,  LUM MELISSA ANNE ,  MELLENCAMP MARK WILLIAM

Inventor： STERNER FRANK JAY ,  GOOVAERTS DANIEL GHISLENA EMIE ,  LUM MELISSA ANNE ,  MELLENCAMP MARK WILLIAM

IPC: A61K39/295 ,  A61K39/193 ,  C12N7/00

CPC classification number: C12N7/00 ,  A61K39/12 ,  A61K2039/521 ,  A61K2039/5252 ,  A61K2039/552 ,  A61K2039/55561 ,  C07K14/005 ,  C12N2770/24034 ,  C12N2770/24122 ,  C12N2770/24134 ,  C12N2770/24161

Abstract: Embodiments of the present invention generally provide an inactivated chimeric virus vaccine and/or immunogenic composition for the treatment or prevention of viral infection. Further, various other mbodiments of the present invention generally relate to methods of preventing and treating virus infection in such animals with the inactivated vaccine and/or immunogenic composition. Other embodiments comprise methods of preparing a vaccine or immunogenic composition for the treatment or prevention of viral infection in such animals.

Abstract translation: 本发明的实施方案通常提供用于治疗或预防病毒感染的灭活的嵌合病毒疫苗和/或免疫原性组合物。 此外，本发明的各种其它实施方案一般涉及用灭活的疫苗和/或免疫原性组合物预防和治疗这些动物中的病毒感染的方法。 其他实施方案包括制备用于治疗或预防这些动物中的病毒感染的疫苗或免疫原性组合物的方法。

公开(公告)号：WO1992002548A1

公开(公告)日：1992-02-20

申请号：PCT/FR1991000432

申请日：1991-05-30

Applicant: INSTITUT PASTEUR ,  DESPRES, Philippe ,  BOULOY, Michèle ,  GIRARD, Marc

Inventor： INSTITUT PASTEUR

IPC: C07K13/00

CPC classification number: C12N15/86 ,  A61K39/00 ,  C07K14/005 ,  C07K16/1081 ,  C12N2710/14143 ,  C12N2770/24034 ,  C12N2770/24122 ,  G01N2333/18 ,  Y02A50/388

Abstract: A recombinant baculovirus comprises a cDNA coding for all or part of antigenic envelope protein E and/or a cDNA coding for all or part of non-structural antigenic protein NS1 of a virus belonging to Flaviviridae or a virus related thereto, and is inserted into the polyhedrin gene between nucleotide + 35 and nucleotide + 170 with the A of the polyhedrin's modified start codon having number + 1. Polypeptides obtained by means of this baculovirus, and the diagnostic and therapeutical uses thereof, are also described.